Escalon(R) Reports Second Quarter Fiscal 20... (AAP adjustments: Stock based comp...)

HOME >> BIOLOGY >> TECHNOLOGY

Escalon(R) Reports Second Quarter Fiscal 2008 Results

Date:2/14/2008

AAP adjustments:

Stock based

compensation $172,911 $123,774 $159,977 $123,774

Depreciation and

amortization $296,328 $282,082 $151,245 $146,803

Total adjustments $469,239 $405,856 $311,222 $270,577

Non-GAAP adjusted

income (loss) $(998,898) $(778,364) $(328,124) $(199,526)

Shares used in

computing fully

diluted earnings

per share 6,388,701 6,346,315 6,389,315 6,347,972

Non-GAAP adjusted

income (loss) per

fully diluted share $(0.16) $(0.12) $(0.05) $(0.03)

Founded in 1987, Escalon develops markets and distributes ophthalmic diagnostic and surgical products as well as vascular access devices. Drew, which operates as a separate business unit, provides instrumentation and consumables for the diagnosis and monitoring of medical disorders in the areas of diabetes, cardiovascular diseases and hematology, as well as veterinary hematology and blood chemistry. The Company seeks to utilize strategic partnerships to help finance its development programs and is also seeking acquisitions to further diversify its product line to achieve critical mass in sales and take better advantage of Escalon's distribution capabilities. Escalon has headquarters in Wayne, Pennsylvania and manufacturing operations in Long Island, New York, New Berlin, Wisconsin, Dallas, Texas, Waterbury, Connecticut and Barrow-in-Furness, U.K.

Note: This press release contains statements that are considered forward- looking under the Private Securities Litigation Reform Act of 1995, including statements about the Company's future prospects. They are based on the Company's current expectations and are subject to a number of uncertainties and risks, and actual results may differ materially. The uncertainties and risks include whether the Company is able to:
-- implement its grow
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. Escalon(R) Announces Promotion of Industry Veteran Barry Durante to President of Sonomed, Inc.
2. Escalon(R) Announces FDA 510(k) Clearance for Sonomed MASTER-VU(TM) B-Scan System
3. Escalon(R) Announces FDA 510(K) Clearance for VascuView(TM) Visual Ultrasound System For Assisted Vascular Access
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. QMed, Inc. Reports July Medicare SNP Enrollments
6. Phlo Affiliate Reports Expanded Coverage to Oregon Border
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
9. Carrington Reports Second Quarter 2007 Results
10. Avitar Reports Third Quarter Financial Results for Fiscal 2007
11. Response Genetics Reports Second Quarter 2007 Financial Results

Post Your Comments:

Escalon(R) Reports Second Quarter Fiscal 20...(AAP adjustments: Stock based comp...)